About US
Contact us
-
FDA tries to protect public from fake Internet pharmaciesWith more Internet pharmacies showing up than the FDA can possibly police, the agency is trying a new tactic tothwart sales of fake or outdated drugs. It has launched a campaign to get the public to2012/9/29
-
Willing Russians help Big Pharma move into market thereAs Russia tries to build its drugmaking infrastructure, it is finding that its citizens are anxious to help by participating in clinical trials. The New York Times reports that while many of the t2012/9/29
-
Sanofi still under pressure to limit French job cutsCall it Sanofi arm-twisting Phase II. Having bullied Sanofi into reducing its planned cuts in France by about 1,000, a French economic development official is whaling at the company again, saying the2012/9/29
-
Bayer cancer drug races through FDA approvalFast track indeed. Only three months after granting accelerated-approval status to Bayer's blockbuster hopeful regorafenib, a treatment for colorectal cancer, FDA gave the drug its final blessing. Bay2012/9/28
-
Pharma racks up $6.6B in fraud penalties so far this yearPharma's 2012 fraud toll? $6.6 billion, says advocacy group Public Citizen. Since January 1, GlaxoSmithKline ($GSK), Johnson & Johnson ($JNJ) and other drugmakers agreed to pay that amount to se2012/9/28
-
Deadbeat Europeans owe drugmakers up to $19.5BWhat's bigger, Big Pharma or Europe's big, bad debt? These days, it's a toss up. According to a new report from the European Federation of Pharmaceutical Industries and Associations, deadbeat states2012/9/27
-
Big Pharma shuns dirt-cheap cancer drugPatients with Type 2 diabetes taking metformin are less likely to develop some forms of cancer, and that has a lot of folks really excited in drug research. But that feeling doesn't carry over to Bi2012/9/27
-
Coca-Cola coaches African health officials on drug-and-vax distributionNovartis ($NVS) CEO Joe Jimenez is only one pharma executive who figures the industry can learn a thing or two from consumer goods. Now, the Bill & Melinda Gates Foundation is expanding a vaccine-2012/9/26
-
Is Valeant's $2.6B price for Medicis too high?Valeant Pharmaceuticals ($VRX) CEO Michael Pearson has a penny-pinching reputation. When it comes to making deals, Pearson drives a hard bargain--or he walks away. But analysts are wondering whether P2012/9/26
-
Regeneron, Vertex, J&J score high in employer rankingsDrugmakers ranked among the world's top employers in two rankings:Science's 2012 survey tagged Regeneron ($REGN) as the best biopharma employer, with Vertex Pharmaceuticals ($VRTX) in second place and2012/9/25